<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746680</url>
  </required_header>
  <id_info>
    <org_study_id>m308RAP11M</org_study_id>
    <nct_id>NCT01746680</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis</brief_title>
  <acronym>TIARA</acronym>
  <official_title>Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to assess the efficacy and safety of tacrolimus in patients with
      active rheumatoid arthritis(RA). EULAR(European League Against Rheumatism) response at week
      24 compared to baseline will be evaluated to assess the efficacy of Tacrolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase IV, Open labeled, Multi-Center Trial to Assess the Efficacy and Safety of
      Tacrolimus(Tacrobell®)in patients with active rheumatoid arthritis(RA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline European League Against Rheumatism(EULAR) response at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Simplified Disease Activity Index(SDAI) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Korean Health Assessment Questionnaire(KHAQ-20) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythrocyte Sedimentation Rate(ESR) at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline Erythrocyte Sedimentation Rate(ESR) at 24weeks</measure>
    <time_frame>baseline, 24eeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline C-Reactive Protein(CRP) at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline C-Reactive Protein(CRP) at 24weeks</measure>
    <time_frame>baseline, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline European League Against Rheumatism(EULAR) response at 16weeks</measure>
    <time_frame>baseline, 16weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus with Methotrexate</intervention_name>
    <description>Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week</description>
    <arm_group_label>Tacrolimus with Methotrexate</arm_group_label>
    <other_name>TacroBell® with MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥20years

          -  Signed and dated informed consent document indicating that the patient

          -  Women of childbearing potential must have a negative serum or urine pregnancy test at
             the screening visit. Except in the case of surgically sterile or amenorrhea for one
             year.

          -  Female patients must agree to use adequate contraception measures during the period of
             therapy which should be continued for 4 weeks.

          -  have RA and meet all of the following criteria; RA occurring ≥ 3months and less than
             15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid
             arthritis; Active RA patients with MTX and among them who has insufficiency response
             to DMARDs as defined DAS28&gt;3.2 in active RA patient. Insufficiency response is defined
             despite MTX therapy for &gt; 12 weeks, RA activity≥ more than moderate and confirmable
             during 12 weeks, sequence of taking MTX &gt;7.5mg/week for more than 6 weeks; ESR≥28mm/h
             or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and Swollen Joint Counts must
             be more than 3

        Exclusion Criteria:

          -  Inflammatory joint diseases, Systematic inflammatory disease

          -  Prosthesis and had an event of infected in it.

          -  Medical history of chronic infection, moderate infection or possibly to life
             threatening or signs and symptoms of serious infection.

          -  Patients have received treatment with a live vaccine from baseline within 8 weeks.

          -  HBsAg positive and hepatitis C virus positive patient.

          -  Patients have a history of malignancy. (But, carcinoma in situ of the uterine cervix
             or basal cell carcinoma have been treated is allowed within 5years)

          -  Patients have cardiovascular disease or associated disease which is not controlled.

          -  uncontrollable blood sugar(HbA1C ≥8%) or required insulin.

          -  Patients with a history of operation on index knee joint which could have influence on
             the result and need to have surgery as determined by investigator.

          -  At screening, patients have laboratory result as defined by ; white blood cell(WBC) &lt;
             3,500/mm3, Absolute Neutrophil Count(ANC) &lt; 1,500/mm3, Hemoglobin &lt; 8.5g/dl, Platelet
             count(PLT) &lt; 100,000/mm3, Serum creatinine &gt;1.5*upper limit of normal or 2mg/dl, Total
             bilirubin &gt; 2*upper limit of normal, aspartate aminotransferase(AST) &gt; 2*upper limit
             of normal, alanine aminotransferase(ALT) &gt; 2*upper limit of normal, alkaline
             phosphatase(ALP) &gt; 2*upper limit of normal

          -  Patients on any other clinical trial or experimental treatment in the past 8weeks

          -  An impossible one who participates in clinical trial by investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung -Jae Hong, phD, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>August 9, 2015</last_update_submitted>
  <last_update_submitted_qc>August 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>Disease Activity Score 28</keyword>
  <keyword>EULAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

